# US 2008/0306157 A1 · Therapeutic intervention to MIMIC the effect of caloric restriction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306157 A1
- Document ID: US20080306157A1
- Status: Published application
- Kind: A1
- Application number: 12/222,482
- Filed: 2008-08-11
- Published: 2008-12-11
- Earliest claimed: 1999-10-13
- Inventors: Marco Chacon
- Web page: https://patentgrep.com/patent/US20080306157A1

## CPC

- A61K 31/215: of carboxylic acids
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods are provided for promoting longevity and decreasing the incidence of aging associated pathologies (e.g., cancer) by the administration of one or more of the following LFFA: linoleic, oleic and palmitic acid. Secondary LFFA derived from this set, as well as their CoA derivatives and synthetic analogs, are effective also in promoting longevity and delaying the onset of age associated disorders. In addition, interventions including LFFA and CoA LFFA formulations are described which protect the organism from acute physical stress, tissue damage and hypoxia (either due to trauma or secondary to surgical procedures.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method of enhancing tolerance of hypoxia comprising:
(a) selecting a mammal, and
(b) administering to said mammal a long chain free fatty acid, its CoA adduct, non-hydrolyzable CoA analogs, derivatives which have greater half-lives, or combinations thereof in an amount sufficient to achieve a systemic level which serves to provide said mammal with a signal equivalent to that experienced during caloric restriction,
whereby hypoxia tolerance is enhanced due to reduction in oxygen consumption.

### Claim 12 (depends on 11)

The method of claim 11, wherein the long chain free fatty acid is palmitic acid, oleic acid, or linoleic acid.

### Claim 13 (depends on 11)

The method of claim 11, wherein the CoA adduct is palmitoyl CoA, oleoyl CoA, or linoleoyl CoA.

### Claim 14 (depends on 11)

The method of claim 11, wherein said mammal:
(a) is suffering from a condition selected from the group consisting of angina, cerebrovascular, myocardial, or peripheral vascular insults, pulmonary embolism, and heart failure;
(b) is in situations involving high altitude, undersea, or outerspace operations;
(c) is a surgical candidate; or
(d) is an athlete.

### Claim 15 (depends on 14)

The method of claim 14, wherein the mammal is suffering from local or systemic hypoxia due to atherosclerotic artery disease or cerebral ischemia.

### Claim 16 (depends on 14)

The method of claim 14, wherein said mammal is a surgical candidate and the administering occurs prior to surgery by an acute course of therapy.

### Claim 17 (depends on 14)

The method of claim 14, wherein said mammal is a surgical candidate and the administering occurs during surgery concomitantly with methods for extracorporeal circulation.

### Claim 18 (depends on 11)

The method of claim 11, wherein the mammal is a human.

### Claim 19

A method improving the health of a mammal comprising:
(a) selecting a mammal, and
(b) administering to said mammal a long chain free fatty acid, its CoA adduct, non-hydrolyzable CoA analogs, derivatives which have greater half-lives, or combinations thereof in an amount sufficient to achieve a systemic level which serves to provide said mammal with a signal equivalent to that experienced during caloric restriction, and
wherein said sufficient amount is determined by monitoring the inhibition of thyroid hormone receptor binding in vivo, inhibition of the Na/K ATPase and Ca ATPase in vivo, conservation of energy fuels, reduction in oxygen consumption, a decrease in core body temperature in said mammal, or activation of protective genes in vivo.

### Claim 20 (depends on 19)

The method of claim 19, wherein the long chain free fatty acid is palmitic acid, oleic acid, or linoleic acid.

### Claim 21 (depends on 19)

The method of claim 19, wherein the CoA adduct is palmitoyl CoA, oleoyl CoA, or linoleoyl CoA.

### Claim 22 (depends on 19)

The method of claim 19, wherein said protective genes are p53, SOD, α-2-globulin, or HSP-70.

### Claim 23 (depends on 19)

The method of claim 19, wherein the mammal is a human.

### Claim 24

A method decreasing angiogenesis a mammal comprising:
(a) selecting a mammal, and
(b) administering to said mammal a long chain free fatty acid, its CoA adduct, non-hydrolyzable CoA analogs, derivatives which have greater half-lives, or combinations thereof in an amount sufficient to achieve a systemic level which serves to provide said mammal with a signal equivalent to that experienced during caloric restriction,
whereby angiogenesis is decreased.

### Claim 25 (depends on 24)

The method of claim 24, wherein the long chain free fatty acid is palmitic acid, oleic acid, or linoleic acid.

### Claim 26 (depends on 24)

The method of claim 24, wherein the CoA adduct is palmitoyl CoA, oleoyl CoA, or linoleoyl CoA.

### Claim 27 (depends on 24)

The method of claim 24, wherein the mammal is a human.
